Abbott Launches Drug Eluting Bioresorbable Vascular Scaffold

Abbott has announced the international launch of a new drug eluting bioresorbable vascular scaffold, according to a news release.

 

The Absorb bioresorbable vascular scaffold is designed for the treatment of coronary artery disease by restoring blood flow to the heart. Absorb then dissolves into the body.

 

"Absorb is a leading example of Abbott's dedication to advancing patient outcomes through innovative technology. Abbott has remained committed to meeting the growing physician and patient demand for a bioresorbable vascular scaffold — from the initial device developed nearly 10 years ago to the expansion of our manufacturing capabilities to support this international launch," said John M. Capek, executive vice president, medical devices, for Abbott, in the release. "We are proud to be the first company to commercialize a drug eluting bioresorbable vascular scaffold, which has the potential to revolutionize the way physicians treat their patients with coronary artery disease."

 

Absorb is now available in Europe, the Middle East, parts of Asia Pacific and parts of Latin America. It is neither approved nor authorized for sale and currently is in development with no regulatory status in the United States.

 

Abbott is headquartered in Abbott Park, Ill.

 

Related Articles on New Technology:

DePuy Mitek Enters Field of Hip Arthroscopy With New ENDURANCE System

Beacon Endoscopic Spin-Off Business to Develop Devices for Digestive System Incisionless Bypass Procedures

New Laser-Based System Designed to Make Injections Painless

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers